Treatment of Established Recurrent Hepatitis C in Liver-Transplant Recipients with Pegylated Interferon-alfa-2b and Ribavirin Therapy

Abstract

Combination pegylated interferon with ribavirin appears to effective therapy in HCV recurrence and in HCV nonresponsive to interferon and ribavirin. This data reveals the difficulty and caution that must be taken when treating HCV-R liver-transplant recipients with combination pegylated alpha-2b interferon and ribavirin therapy.